ArticleItalian journal of pediatrics2025
Inhaled nitric oxide therapy in preterm infants born before 34 weeks of gestation: a nationwide multicenter study.
Article in Italian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundDespite the lack of consensus, the use of inhaled nitric oxide (iNO) in preterm infants with a gestational age (GA) of less than 34 weeks has been increasing in recent years. At present, there are no multi-center studies in China on the use of iNO in this population. This study aims to investigate the use of iNO in preterm infants under 34 weeks of gestation over the past 10 years in China, and provides evidence-based medical proof for the use of iNO in these neonates.
methodsUsing a retrospective study method, clinical data were collected from infants with a GA of less than 34 weeks who received iNO therapy in the neonatal units of five tertiary hospitals in China from January 2013 to December 2022. The infants were divided into two groups: Group A (2013-2017) and Group B (2018-2022). The differences in clinical characteristics, iNO use, and short-term outcomes between the two groups were analyzed.
resultsOver the past decade, the use of iNO in preterm infants with a GA of less than 34 weeks has increased gradually, with a more pronounced rise in its use among preterm infants born at 24-27 weeks. The proportion of infants receiving iNO therapy has increased from 1.23% (Group A) to 2.62% (Group B). Compared to Group A, the infants in Group B who received iNO therapy had a smaller GA and lower birth weight. The initial and maximum doses of iNO in Group B were higher (10.0 ppm vs. 8.0 ppm, 15.0 ppm vs. 9.0 ppm). More than half of the extremely preterm infants (EPI) and extremely low birth weight infants (ELBWI) died in both groups. In preterm infants with a GA of 32-33 weeks who were treated with iNO, the case fatality rate was significantly lower in Group B compared to Group A (9.1% vs. 28.2%).
conclusionThe use of iNO in preterm infants with a GA of < 34 weeks has increased over the past 10 years. The treatment strategy for iNO has become more aggressive, and the observed reduction in mortality among relatively older preterm infants (32-33 weeks GA) may be linked to increased iNO utilization and higher dosing regimens. Notably, the case fatality rate among EPI and ELBWI remains elevated throughout the study period, with no statistically significant differences observed between the two groups. Given the benefits and risks of iNO therapy, routine use in EPI and ELBWI may not be advisable.
trial registrationThis article is a retrospective registered study, registered under the number ChiCTR2200066935 on December 21, 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.